Submit manuscript

Level of Anti-SARS-CoV-2 Spike Protein amongst Frontline Health Personnel of a Supra-Tertiary Hospital

Thanaphoom Aupongkaroon¹, Naesinee Chaiear¹, Phanumas Krisorn¹, Patimaporn Chanpho², Nucharat Moolmueangsaen², Songsak Kiatchoosakun³

Affiliation : ¹ Department of Community, Family and Occupation Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; ² Office of Occupational Health and Safety, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; ³ Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Background: COVID-19 has become a global pandemic, leading to the development of various vaccines to protect against infection. Sinovac- CoronaVac COVID-19 vaccine, an inactivated virus vaccine developed by Sinovac Biotech, has been approved for use. However, limited information is available regarding the immunity level provided by Sinovac-CoronaVac.
Objective: To determine the level of anti-SARS-CoV-2 spike protein antibodies 28 and 90 days after the administration of the second dose of CoronaVac.
Materials and Methods: A descriptive study was conducted, involving 132 healthcare personnel. The antibody levels were measured using the Roche Elecsys anti-SARS-CoV-2 spike protein immunoassay, both at 28 and 90 days after the second dose of CoronaVac.
Results: The majority of participants were female registered nurses. The geometric mean antibody levels on day 28 and 90 were 138.1±2.2 and 66.9±0.3, respectively. By day 90, the antibody levels had declined to 45.3% compared to day 28. Nearly all participants had immunity levels on day 90 lower than those resulting from natural infection.
Conclusion: The present study findings indicated that the immunity level, as measured by anti-SARS-CoV-2 spike protein antibodies, declined below the level observed with natural infection by day 90. Additional vaccine doses are suggested for healthcare personnel to provide rapid protection of the infection.

Received 20 March 2023 | Revised 31 May 2023 | Accepted 2 June 2023
DOI: 10.35755/jmedassocthai.2023.07.13819

Keywords : Antibody level; COVID-19; Health care personnel; Immunity


All Articles Download


INFORMATION

Contact info

JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com

JMed Assoc Thai
MEDICAL ASSOCIATION OF THAILAND
ISSN: 0125-2208 (Print),
ISSN: 2408-1981 (Online)
The content of this site is intended for health professionals.

Submissions

» Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement

Other

» Journal Sponsorship » Site Map » About this Publishing System

© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.